Lantern Pharma (LTRN) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Lantern Pharma in October 2026.
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma (LTRN) Stock Forecast
Analyst price target, next 12 months
$14.00
+1366.9% vs today's $0.95
Price range over the last 12 months
Close to its 12-month low
Analysts covering Lantern Pharma have a consensus 12-month target of $14.00, above the current price of $0.95.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lantern Pharma's stock, anticipating significant growth potential with a target price of $14.
Financial Health
Lantern Pharma is showing solid cash flow, indicating good financial health and operational efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
